EUCTR2011-005981-39-ESActive, not recruitingPhase 1
Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily - KMO
nidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge0 sitesStarted: January 30, 2012Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Patients older than 18, HIV positive
- •2. Patients treated in monotherapy regimen (Lopinavir/ritonavir twice daily, 2-0-2), without any changes in the treatment regimen during the last 6 months
- •3. Indetectable viral load (<40 copies/ml) during the last 6 months
- •4. Patients that accept the participation in the sudy and sign the ICF
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Opportunistic disease, neoplasy or any other active disease with specific treatment
- •2. Active addiction to ilegal drugs or active use of psychotropic drugs
- •3. Mental retardation diagnosis, or mental dementia or severe psychiatric disease (excluding major depression disorder solved > 3 months)
Investigators
Similar Trials
Completed
Phase 4
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once DailyHIVNCT01581853Daniel Podzamczer21
Active, not recruiting
Phase 1
A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Raltegravir 400 mg Twice-Daily in Antiretroviral-Naïve, HIV-1 Infected SubjectsEUCTR2008-000881-22-FRAbbott GmbH & Co. KG200
Active, not recruiting
Not Applicable
A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Raltegravir 400 mg Twice-Daily in Antiretroviral-Naïve, HIV-1 Infected SubjectsEstudio aleatorizado y abierto de 400/100 mg de lopinavir/ritonavir en comprimidos dos veces al día + coformulación de emtricitabina/tenofovir disoproxil fumarato, 200/300 mg una vez al día, frente a 400/100 mg de lopinavir/ritonavir en comprimidos dos veces al día + raltegravir, 400 mg dos veces al día, en sujetos infectados por el VIH-1 sin tratamiento antirretroviral previo.Treatment-naïve, HIV-1 infected subjectsSujetos infectados por el VIH-1 sin tratamiento antirretroviral previo.MedDRA version: 9.1Level: LLTClassification code 10020162Term: HIV infection CDC Group IEUCTR2008-000881-22-ESAbbott GmbH & Co. KG200
Active, not recruiting
Not Applicable
A randomized, open-label, study of lopinavir/ritonavir 400/100 mg tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily versus lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily in antiretroviral-naive, HIV-1 infected subjects. - NDEUCTR2008-000881-22-ITAbbott GmbH & Co. KG200
Completed
Phase 2
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected SubjectsHIV InfectionsNCT00075231Abbott150